» Articles » PMID: 19161745

Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer is Associated with Enhanced Survival

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2009 Jan 24
PMID 19161745
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach.

Methods: From January 1998 through December 2003, all patients from a single institution receiving neoadjuvant chemoradiotherapy followed by esophagogastrectomy were reviewed for operative mortality, morbidity, long-term survival, and factors affecting survival. Only patients preoperatively staged with both computed tomographic scans and endoscopic ultrasound were included.

Results: There were 162 patients (142 men, 20 women), and the median age was 61 years (range, 22 to 81 years). Histopathology was adenocarcinoma in 143 patients and squamous cell in 19. Pretreatment clinical stage was II in 28 patients (17%), III in 111 (68%), and IV (M1a) in 23 (14%). Ivor Lewis esophagogastrectomy was the most common procedure, occurring in 132 patients. Operative mortality and morbidity was 4.9% and 37%, respectively. Pathologic response was complete in 42 patients (26%), near complete in 27 (17%), partial in 88 (54%), and unresectable in 5 (3%). Five-year survival for overall, complete, near complete, and partial response patients was 34%, 55%, 27%, and 27%, respectively (p = 0.013). Patients whose lymph nodes were rendered free of cancer showed improved overall and disease-free survival compared with patients having persistently positive lymph nodes (p = 0.019).

Conclusions: Esophagogastrectomy after neoadjuvant chemoradiotherapy can be performed with low mortality and morbidity. Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses. Future efforts should be directed at understanding determinants of complete responses.

Citing Articles

A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients.

Qi Y, Hu Y, Lin C, Song G, Shi L, Zhu H Front Immunol. 2025; 16:1530279.

PMID: 39958355 PMC: 11827421. DOI: 10.3389/fimmu.2025.1530279.


Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.

Zhao F, Wang Q, Han W, Maitudi W, Cao F, Zhang T Cancer Med. 2025; 14(4):e70676.

PMID: 39945301 PMC: 11822455. DOI: 10.1002/cam4.70676.


Do socioeconomic factors impair uptake of neoadjuvant therapy for patients with locoregional oesophageal cancer?.

Jindani R, Rodriguez-Quintero J, Quintero-Rodriguez J, Loh I, Ha G, Olivera J Eur J Cardiothorac Surg. 2025; 67(1.

PMID: 39798126 PMC: 11739619. DOI: 10.1093/ejcts/ezae462.


Tumor-Infiltrating Lymphocytes in Resected Esophageal and Gastric Adenocarcinomas Do Not Correlate with Tumor Regression Score After Neoadjuvant Chemotherapy: Results of a Case-Series Study.

Seretis F, Glava C, Smparounis S, Riga D, Karantzikos G, Theochari M Cancers (Basel). 2024; 16(21).

PMID: 39518132 PMC: 11545232. DOI: 10.3390/cancers16213694.


Prediction of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma Using Preoperative Serum Small Ribonucleic Acid Obtained After Neoadjuvant Chemoradiotherapy.

Hirohata R, Yamamoto Y, Mimae T, Hamai Y, Ibuki Y, Takahashi R Ann Surg Oncol. 2024; 32(1):570-580.

PMID: 39419890 PMC: 11659344. DOI: 10.1245/s10434-024-16247-z.


References
1.
Leichman L, STEIGER Z, SEYDEL H, Dindogru A, Kinzie J, Toben S . Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol. 1984; 2(2):75-9. DOI: 10.1200/JCO.1984.2.2.75. View

2.
Vigneswaran W, Trastek V, Pairolero P, Deschamps C, Daly R, Allen M . Transhiatal esophagectomy for carcinoma of the esophagus. Ann Thorac Surg. 1993; 56(4):838-44; discussion 844-6. DOI: 10.1016/0003-4975(93)90341-e. View

3.
Rizk N, Venkatraman E, Bains M, Park B, Flores R, Tang L . American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007; 25(5):507-12. DOI: 10.1200/JCO.2006.08.0101. View

4.
Agarwal B, Swisher S, Ajani J, Kelly K, Komaki R, Abu-Hamda E . Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005; 79(5):1716-23. DOI: 10.1016/j.athoracsur.2004.10.026. View

5.
Rizk N, Venkatraman E, Park B, Flores R, Bains M, Rusch V . The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006; 132(6):1374-81. DOI: 10.1016/j.jtcvs.2006.07.039. View